Purpose The PET radioligand [
Introduction
The immune surveillance system in brain is thought to play a role in the pathogenesis of a number of severe medical conditions, including multiple sclerosis, Parkinson's disease, Alzheimer's disease and psychiatric disorders such as schizophrenia. The development of methodology to examine immune activation in the brain is thus of central interest in research on CNS disorders. Microglia cells are considered the resident macrophages of the brain, responsible for phagocytosis of cellular debris, antigen presentation and a variety of other functions including cytokine signalling [1, 2] .
Microglia cells express the translocator protein (TSPO), an intracellular protein formerly known as the peripheral benzodiazepine receptor [3] . With molecular imaging techniques, such as PET, it is possible to measure TSPO levels in the brain. [ 11 C]PK11195 is the most widely used radioligand for this purpose [4] . However, this radioligand has some disadvantages, such as a low specific to nonspecific binding ratio [5] . In addition, a recent test-retest study in control subjects showed only moderate intraindividual reproducibility in [ 11 C]PK11195 binding [6] , as compared to commonly used neuroreceptor radioligands such as [ 11 C]raclopride [7] . More recently, several novel TSPO radioligands with improved characteristics have been developed [8] . Of these, [ 11 C]PBR28 is a promising candidate which, in a comparison with [
11 C]PK11195, shows higher specific binding and better kinetic properties [5, 9, 10] . [ 11 C]PBR28 has been used to show changes in TSPO binding in an increasing number of clinical studies [11] [12] [13] [14] . However, information on the testretest reproducibility of [ The primary aim of this PET study was to examine the reproducibility of [ 11 C]PBR28 binding in healthy control subjects. A secondary aim was to compare the standard ROIbased compartmental analysis with a parametric approach for quantification of [ 11 C]PBR28 binding. Moreover, in a preliminary analysis of diurnal changes in TSPO binding [15, 16] , the study was designed so that six subjects were examined in the morning and afternoon on the same day, and six subjects at the same time in the morning on on two separate days.
Materials and methods

Subjects
The study was conducted at the Karolinska University Hospital, Solna, Sweden, and was approved by the regional Ethics Committee in Stockholm and the Radiation Safety Committee at the Karolinska University Hospital, Stockholm.
Subjects were recruited by advertisement and provided written informed consent. They were healthy according to medical history, clinical examination and routine laboratory blood and urine tests. All subjects were assessed by a senior psychiatrist (K.C.), using the Mini International Neuropsychiatric Interview (MINI) for psychiatric diagnoses. None of the subjects had previously been exposed to psychopharmacological medication. Furthermore, a negative illegal drug screening test was ascertained in all subjects prior to PET examination. None of the subjects were on any medication at the time of the study. No brain abnormality was detected on MRI as evaluated by a neuroradiologist at the MR Centre, Karolinska University Hospital, Solna.
As demonstrated both in vitro and in vivo, [
11 C]PBR28 binding is influenced by an identified single point mutation in the TSPO gene [8, 17] . At screening, a blood sample was collected and genotyping was performed according to the description below. In total, 15 subjects were recruited. Of these, one was a low affinity binder and was therefore excluded from the analysis. Two additional subjects were excluded because of technical issues with the PET measurements. The remaining 12 subjects comprised six men and six women, with a mean age of 23.9±3.1 years. Six were high affinity binders (HAB) and six were mixed affinity binders (MAB).
Study design
Six subjects were examined with PET in the morning and in the afternoon on the same day, and six in the morning of two separate days 2-5 days apart. Both gender and binding affinity were equally distributed in the two groups. For the individuals examined twice on the same day, the average interval between measurements was 3 h 25 min. For the subjects examined on two separate days, the mean interval was 3.3 days, and the mean difference between injection times was 20 min.
Genotyping
TSPO genotype was assessed using a TaqMan based polymerase chain reaction (Applied Biosystems® QuantStudio™ 7) assay specific for the rs6971 polymorphism (Applied Biosystems, C_2512465_20, cat. no. 4351379) in the TSPO gene. In brief, genomic DNA was extracted from 8 ml of whole blood (QIAamp® DNA Blood Maxi) and DNA was diluted in DNase-free water before the test, to give a final amount of 20 ng/well. Each DNA sample was plated and mixed with 2× TaqMan Genotyping mix (Applied Biosystems) in a 384-well microtitre plate (MicroAmp Optical 384-well reaction plate; Applied Biosystems) to a final reaction volume of 5 μl. The DNA extraction and TaqMan PCR were performed according to the manufacturer's instructions.
Magnetic resonance imaging
Brain MRI was performed using a 3-T General Electric Discovery MR750 system (GE, Milwaukee, WI). T2-weighted images were acquired for clinical evaluation regarding pathology, and T1-weighted images were acquired for coregistration with PET images and definition of anatomical brain regions.
Radiochemistry
Radiosynthesis was performed according to the method of Briard et al. with modification [18] . Briefly, [ 11 C]PBR28 was produced by [ helmets were made for each subject and used with a head fixation system to minimize movement artefacts and to reproduce the head position in each examination [19] . The subjects were placed recumbent with their head in the PET system. A cannula was inserted into the left radial artery and another one into the right cubital vein. A sterile phosphate buffer (pH 7.4) containing radioligand was injected as a bolus over approximately 10 s into the cubital vein. The cannula was then immediately flushed with 10 mL saline solution.
PET measurements were obtained using a high resolution research tomograph (Siemens Molecular Imaging, Knoxville, TN). The axial field of view was 25.2 cm, corresponding to 207 planes in the reconstructed images, with a pixel size of 1.218×1.218×1.218 mm. For attenuation correction a 6-min transmission measurement was acquired using a single 137 Cs source. Brain radioactivity was acquired in a consecutive series of time frames for up to 91 min, except in one individual, in whom the acquisition time was 60 min because of technical problems. List mode data were reconstructed using the ordinary Poisson three-dimensional (3D) ordered subsets expectation maximization algorithm, with ten iterations and 16 subsets including modelling of the point spread function. The corresponding in-plane resolution with the ordinary Poisson 3D ordered subsets expectation maximization point spread function was 1.5 mm in the centre of the field of view and 2.4 mm at 10-cm off-centre directions [20] .
Arterial blood sampling
An automated blood sampling system (ABSS) was used during the first 5 min of each PET measurement [21] . After that, arterial blood samples (1-3 mL) were drawn manually at 1, 3, 5, 7, 9, 10.5, 20, 30, 40, 50, 60, 70, 80 and 90 min. The radioactivity was measured immediately afterwards in a well counter cross-calibrated with the PET system. After centrifugation, 0.8-1.5 mL plasma was pipetted and the radioactivity was measured in the same well counter.
Radiometabolite and plasma protein binding analysis
A reverse-phase HPLC method was used to determine the percentages of radioactivity in the plasma that corresponded to unchanged radioligand and radiometabolites during the course of each PET measurement. The plasma (0.7-1.5 mL) obtained after centrifugation of blood at 2,000 g for 2-4 min was mixed with 1.4 times the volume of acetonitrile. After stirring with a vortex mixer, the sample was centrifuged at 2, 000 g for 4 min, and 1.5 mL of water was added to the supernatant plasma/acetonitrile mixture, which was then injected into a radio-HPLC system. Blood (2-4 mL) and plasma (0.7-1.5 mL) samples were counted in a NaI well-counter. The radio-HPLC system used consisted of an interface module (D-7000; Hitachi, Tokyo, Japan), a L-7100 pump (Hitachi), an injector (model 7125, with a 5.0-mL loop; Rheodyne, Cotati, CA) equipped with a μBondapak C18 column (300 × 7.8 mm, 10 μm; Waters, Milford, MA), and an ultraviolet absorption detector (L-7400, 254 nm; Hitachi) in series with a 150TR Packard scintillation analyser (housed in a 50-mm thick lead shield) equipped with a 550 μL flow cell. Acetonitrile (A) and ammonium formate (100 mM) (B) were used as the mobile phase at 6.0 mL/min, according to The free fraction, f p =C free /C total , of [ 11 C]PBR28 in plasma was estimated using an ultrafiltration (Centrifree YM-30; Millipore) method. Equal amounts of [ 11 C]PBR28 were added to both plasma and phosphate-buffered saline (control solution) and the radioactivity was counted with a NaI wellcounter before (C total ) and after (C free ) ultrafiltration. The results were corrected for membrane binding measured with the control samples. For each PET examination a mean f p value was calculated based on six measurements.
Image analysis
Image preprocessing T1-weighted MR images were reoriented so that the line between the anterior and posterior commissure was in the horizontal plane and the interhemispheric fissure in the sagittal plane. MR images were segmented into grey matter (GM) and white matter (WM) and cerebrospinal fluid using the SPM5 segmentation algorithm in MATLAB (Wellcome Trust Centre for Neuroimaging, London, UK; The Mathworks, Natick, MA). PET images were corrected for head movement using a frame-by-frame realignment algorithm, in which all frames were individually realigned to the first minute of acquisition. The 4D PET images were integrated over time to obtain 3D PET summation images, and the reoriented MR images were then coregistered to the 3D PET summation images, yielding parameters of rotation and translation. The spatial processing of the MR and PET images was performed in SPM5.
Region of interest definition
Regions of interest (ROIs) were obtained using the Automated Anatomical Labelling system [22] in SPM5 and applied to the dynamic PET images using coregistration parameters to create time-activity curves. The primary ROI was brain GM. In addition we quantified regional binding in the thalamus, putamen, hippocampus, lateral frontal cortex and lateral temporal cortex, which are all brain regions of interest in research on the role of immune activation in neuropsychiatric disorders. Furthermore, a composite volume was also created for the WM.
Metabolite corrected arterial plasma input function
Preprocessing of arterial blood data was performed using Kaleidagraph 4.1 software (Synergy Software). First, dispersion correction was performed. Arterial blood data from the manual samples were then linearly interpolated to obtain curves with one data point per second up to the end of the PET acquisition. Blood time-activity curves were generated by integrating the initial automated blood sampling system curve with the interpolated curve from manual blood samples. Plasma and blood radioactivity concentrations from the manual blood samples were divided to obtain a time curve for the plasma-to-blood ratio for the first 5 min. The first 5 min of the blood curve was then multiplied by the plasma-to-blood ratio curve to obtain an estimate of the plasma curve. The remaining part of the plasma curve was generated by linear interpolation using the discrete direct plasma measurements. Correction for radioligand metabolism was performed in PMOD v3.2 (pixel-wise modelling software; PMOD Technologies Ltd., Zurich, Switzerland) using the parent fraction. Individual parent fraction data were fitted using a three-exponential model.
Quantification of [ 11 C]PBR28 binding
For the main analysis of reproducibility, [ 11 C]PBR28 binding was quantified using the two-tissue compartment model (2TCM) with a metabolite-corrected arterial plasma curve as input function using PMOD v3.2 software. In addition, [ 11 C]PBR28 binding was estimated using a voxel-by-voxel approach based on parametric images. Since V T has been shown to increase over time [9] , and since a shorter examination time would be beneficial in clinical studies, analyses were made for acquisition times of both 91 and 63 min. Finally, standardized uptake values (SUV) were calculated for the GM and plasma to assess the contribution of variance from the brain and plasma measurements, respectively.
The two-tissue compartment model
The two tissue compartments are defined as the radioactivity concentration of nondisplaceable radioligand in the brain (C ND ) and the radioactivity concentration of radioligand specifically bound to receptors (C S ). In this model, four rate constants (K 1 , k 2 , k 3 and k 4 ) are used to interpret the regional time curves for the radioligand in the brain. This model has previously been shown to be suitable for the quantification of [ 11 C]PBR28 binding [9] .
The rate constants were estimated by curve fitting using a least-squares approach. The blood volume fraction was set to a fixed value of 5 %. Regional [ 11 C]PBR28 binding was expressed as the total volume of distribution (V T ), which is the sum of both specific and nondisplaceable binding [23] . V T equals the ratio at steady state of the concentration of radioligand in the brain to that in the plasma, and can be calculated according to the following equation
Parametric images
Parametric images were generated using the wavelet-aided parametric imaging (WAPI) method, with the stationary wavelet transform-based parametric mapping framework implemented in MATLAB R2007b for Windows [24] . The original dynamic PET images were transformed frame-by-frame to the wavelet space using a 3D stationary wavelet transform in an iterative process which separates the high spatial frequencies from the low, using wavelet decomposition filters with finite support. The high-frequency component is retained, whereas the low-frequency component is separated at the next iteration into high and low frequencies using filters with different cutoff frequencies. The parameters of the filter kernel (length of the wavelet filters) and the depth of decomposition (optimal number of iterations) have previously been optimized to 16 and 3, respectively [25] . Quantification was performed with Logan's graphical analysis using multilinear regression to fit the linear part of the curve of the coefficients from the dynamic wavelet transform [26] . The parametric wavelet transform describing the distribution of the total distribution volume (V T ) was then transformed to a 3D parametric map of V T in normal space. The analysis was based on the last 60 min (for the 91-min acquisition) and 36 min (for the 63-min acquisition). The GM ROI was then applied to the WAPI images to enable comparison with the V T obtained using the 2TCM.
Radioligand uptake in brain and plasma
SUVs were calculated for [
11 C]PBR28 in GM and plasma by normalizing radioactivity measures to the subject weight and injected radioactivity. The area under the curve (AUC) was then calculated for the whole time-frame of the measurements.
Statistics
The absolute variability, V, was expressed as the difference in V T between the first and second PET scans (PET1 and PET2) relative to the mean of the two values according to the following equation:
The intraclass correlation coefficient (ICC) is a measure of reliability, as indicated by the proportion of the variability in the data that is attributable to differences between methods, for instance between test and retest measurements. ICC ranges between 0 and 1, where values close to 1 indicate that the dominant proportion of the variability originates from variation between subjects. The ICC was calculated according to the following equation:
This version of ICC has been defined as ICC (A,1) by McGraw and Wong [27] . In the equation above, k and n denote the number of observations and subjects, respectively, and MSS subj , MSS meth and MSS error denote the mean sum of squares for the subjects, methods, and residual error respectively. To assess the direction of change between PET1 and PET2, the difference in V T between the two measurements relative to the V T of PET1, (D), was calculated as follows:
The effect of gender and genotype on the reproducibility of [ 11 C]PBR28 binding was assessed using the MannWhitney U test. Differences between methods of quantification, as well as injected radioactivity and mass between PET1 and PET2 in all subjects, were tested using the paired t test. Differences between morning and afternoon [
11 C]PBR28 binding measurements in the subgroup of six subjects, as well as differences in injected radioactivity, specific radioactivity and injected mass in the two subgroups, were tested using the related samples Wilcoxon signed ranks test. Statistical analyses were performed using IBM SPSS Statistics 22 (Armonk, NY). In addition, absolute variability according to Eq. 2 was calculated on a voxel-by-voxel basis using WAPI parametric images and a batch image calculator for SPM (http:// robjellis.net/spm-tools.html). For that purpose, parametric images were spatially normalized using the transformation matrix obtained in the above analyses, followed by smoothing with an 8-mm FWHM isotropic Gaussian kernel.
Results
Following intravenous injection, [
11 C]PBR28 appeared rapidly in the brain and was homogenously distributed across all brain regions (Fig. 1) . Twelve subjects underwent two PET measurements according to the protocol, except one subject in whom data acquisition was limited to 60 min in PET2. The values derived from this single examination were carried forward to the 63-min and 91-min analyses. The mean injected radioactivities in PET1 and PET2 were 379±61 and 410±37 MBq, respectively ( Table 1) . The difference was statistically significant (p=0.046). Examining the two groups separately, a difference was found only in the subjects examined on separate days (357 ± 75 vs. 417 ± 33 MBq, p = 0.028). Mean injected masses also showed a difference, with higher levels in PET2 (0.53 ± 0.26 and 0.61 ± 0.3 MBq, respectively, p=0.041). There was no significant difference in injected mass between PET1 and PET2 in either subgroups.
Reproducibility in radioligand uptake and free fraction in plasma
The absolute variability in [ 11 C]PBR28 uptake in the GM was 14.6 %, whereas the corresponding variability in plasma was 17.4 %. The change in GM SUV AUC between PET1 and PET2 for the subjects examined on the same day was not statistically significant. In contrast, a 22.4 % decrease in plasma SUV was observed (p=0.028). The absolute variability in f p was 23.9±13 %.
Reproducibility of V T : 2TCM
V T in the GM calculated using the 2TCM was the primary endpoint in the present analysis of reproducibility. The individual V T in the GM varied between 1.3 and 7.8 ( Fig. 2 , Table 1 ). The differences in V T between PET1 and PET2 (2TCM) for all brain regions are shown in Table 2 . The absolute variability in V T in the GM was 18.3±12.7 %. The regional ICC values ranged from 0.90 to 0.94, except in the WM (0.32), a region in which the interindividual variability was also high (48.3±39.8 %). The values of V T ICC in the GM calculated separately for the genetic groups were 0.89 for HABs and 0.91 for MABs. Reducing the time of analysis to 63 min yielded similar values for the variability in V T (16.9± 14.9 %) ( Table 3) . Although the absolute variation was numerically lower in the subjects examined on separate days, as compared to those examined on the same day (15.9±12.2 vs. 20.7±20.7), the difference was not significant (p=0.59). The difference in GM V T between morning and afternoon examinations in subjects examined on the same day was not significant for the 91-min analysis (p=0.116), but the difference was significant for the 63-min analysis (p=0.028) ( Table 3) . Mean values and reproducibility measures for the individual rate constants are shown in Table 4 .
Effect of genotype on [ 11 C]PBR28 binding and reproducibility
The values of regional V T in the GM, quantified using 2TCM, in each subject and PET examination are shown in Table 1 . The HAB subjects showed an average GM V T of 4.3 ± 1.8 for both measurements combined. In MAB subjects the corresponding value was lower (2.6 ± 1.1). One HAB subject showed markedly higher V T values (7.7 and 7.8 in PET1 and PET2, respectively). The regional V T values (2TCM) in subjects examined on the same day and in those examined on separate days, as well as the mean for all subjects, are shown in Table 2 . There was no effect of genotype on absolute variability (17.6 % in MAB subjects vs. 19.1 % in HAB subjects; p=1.00).
Parametric images
V T in the GM in all subjects, as quantified using WAPI, ranged between 1.3 and 7.7. There was a high degree of correlation with the 2TCM-derived values (r=0.989, p<0.001, all GM values combined, n=24). The absolute variability in V T in Fig. 1 Representative figure using data from subject 2 showing the twotissue compartment model fit to the time-activity curves for the grey matter (GM), thalamus (Tha), lateral frontal cortex (LFC), and hippocampus (Hip) the GM, as derived using WAPI, was 17.8±12.7 % (Table 3. ). The mean difference in absolute variability between the two methods of quantification, 2TCM and WAPI, was 0.6±9.0 % (p=0.838). The difference in WAPI-generated GM V T values between the morning and afternoon examinations was statistically significant for both the 91-min and 63-min analysis (p= 0.028). Colour-coded maps of voxel-wise absolute variability are shown in Fig. 3 . In accord with the ROI analysis, absolute variability in GM regions was in the range of 5-25 %, whereas in WM regions values were above 30 %. There were no GM regions with particularly high or low variability.
Discussion
In this PET study we examined the test-retest reproducibility of [ 11 C]PBR28 in 12 healthy subjects by determining the regional volume of distribution of radioligand binding (V T ) in two consecutive PET examinations. The mean absolute variability in [ 11 C]PBR28 binding in GM regions ranged from 13.8 % to 25.9 % depending on the region examined and the method of quantification used, and whether or not diurnal changes were controlled for. The reliability was high, with ICC values for V T in all GM regions ranging from 0.90 to [6] . In this study examinations were performed on average 6 weeks apart. In order to compare the results with those of the present study, we calculated the mean absolute variability based on the reported rate constants, and found it to be 15.9 % for V T in the GM. The absolute variabilities in GM binding of the two radioligands can thus be regarded as very similar. In contrast, the ICC value for the GM was much lower (0.47) for [ 11 C]PK11195. Furthermore, in specific brain regions, the mean difference in binding potential of [ 11 C]PK11195 was substantially higher than the regional differences in V T , and ICC values were very low (ranging from negative to 0.57). Although there were some differences in study design, including the use of different outcome measures of radioligand binding, the present analysis suggests that [ 11 C]PBR28 is more reliable for measuring TSPO levels, in particular at an anatomically detailed level.
A mathematical explanation for the apparent discrepancy of high variability and high ICC values when comparing [6] , it was 49 % in the present study. After removing the very high V T values from one subject, the variability was 36 %. This range of intersubject variability is well in line with other [ 11 C]PBR28 studies in healthy subjects using 2TCM and V T as outcome [9, 28, 29] .
Approximately 10 % of humans lack specific binding of [ 11 C]PBR28 to TSPO [10] , that depends on a specific polymorphism in the TSPO gene [17] . This variation in binding affinity is a shared feature of all tested second-generation TSPO ligands, as shown by in vitro studies [17] . In this study we confirmed previous findings of an effect of genotype on [ 11 C]PBR28 binding in vivo. The V T in high-affinity binders was approximately 65 % higher than that in mixed-affinity binders (2TCM). This difference is larger than that found in recent studies of [ 11 C]PBR28 binding in terms of SUVs (30 % difference [30] ) and V T (30-40 % difference [29, 31] ), although the discrepancy was highly influenced by the outlier data from one subject in the HAB group. Importantly, we were not able to show an effect of genotype on test-retest reproducibility, suggesting that genotype does not have to be controlled for in clinical studies with a within-subject experimental design.
Apart from the effect of TSPO genotype, the relatively high intraindividual and interindividual variance in [
11 C]PBR28 binding may be influenced by biological factors related to TSPO as a target, in addition to random noise. It is known that the amount of specific immune cells, such as monocytes, neutrophils and lymphocytes, and cytokines show a 24-hour variation in plasma [32] . For instance, circadian changes in the levels of IL-6 have recently been demonstrated in both plasma and CSF of healthy controls [33] . The observation that cytokines have been shown to increase TSPO levels [2] has attracted attention to diurnal changes in TSPO radioligand binding. In this study, there was no difference in the variability of V T between subjects examined at the same time of day and those examined in the morning and afternoon. However, there was an increase at the level of a trend of 2TCM-based GM, V T , between the morning and afternoon measurements, and significant increases in WAPI-based and 63-min 2TCM GM V T values. Moreover, a significant decrease was shown in plasma AUC. Although these preliminary findings in a limited sample cannot be regarded as conclusive, diurnal changes in TSPO binding may potentially be a confounder in clinical studies and further investigation of the issue is thus warranted.
The reproducibility values from the ROI-based compartmental analysis and the voxel-based quantification approach were in agreement. This may be of interest for clinical studies, since changes in the immune system in neuropsychiatric disorders may not follow anatomical boundaries [13] . A parametric approach for the analysis of TSPO binding can thus be a useful addition. Furthermore, variability remained unchanged when reducing the time of analysis from 91 to 63 min. This observation suggests that a shorter time-frame for data acquisition may be used, in particular in clinical populations in which long scanning times can present a practical problem.
As for all other TSPO radioligands, quantification of binding is dependent on the use of a metabolite-corrected arterial input function. The reason is that there is no brain region devoid of TSPO that can be used as reference, as has been confirmed in a recent blocking study [31] . The use of blood data potentially represents another methodological source of variance, since several analysis steps are introduced. In particular, [ 11 C]PBR28 shows rapid metabolism, resulting in low levels of parent compound remaining at the end of the examination. Thus, even small errors introduced at this stage may propagate to having an effect on V T . In the present study, variability in plasma uptake was at the same level as the variability in GM uptake. Assuming that part of this variation was methodologically determined, this suggests that reproducibility could be further improved if this component of the analysis were removed. An important aim for future research will therefore be to investigate methods for [
11 C]PBR28 quantification without the need for arterial blood sampling, such as the use of an image-derived input function [34] in relation to testretest reproducibility.
Conclusion
In the present study we found a low to medium reproducibility but high reliability in [ 11 C]PBR28 binding, irrespective of the method of quantification used. The results suggest that the radioligand is suitable for both within-subject and group comparisons, and that an examination length of 63 min could be sufficient for clinical studies. Furthermore, parametric approaches may be used to enable quantification of TSPO binding independent of anatomical ROI definition. Finally, if our preliminary findings on diurnal changes in measures of TSPO availability are confirmed, controlling for time of examination in clinical studies would become necessary.
